Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential - Wikidata - thesis-toulmin - TriplyDB

Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

http://www.wikidata.org/entity/Q27676429

about

Moving targets: Emerging roles for MMPs in cancer progression and metastasis ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis Milestones in contraceptive vaccines development and hurdles in their application Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease.PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1)Prognostic value of tissue inhibitor of metalloproteinase-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.New strategies for targeting matrix metalloproteinases Matrix metalloproteinases as breast cancer drivers and therapeutic targets.Association of MMP-2 gene haplotypes with thoracic aortic dissection in chinese han population.Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification.Host-parasite interaction: parasite-derived and -induced proteases that degrade human extracellular matrix.Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies IGF-IR cooperates with ERα to inhibit breast cancer cell aggressiveness by regulating the expression and localisation of ECM molecules The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke.New approaches to selectively target cancer-associated matrix metalloproteinase activity.TIMPs: versatile extracellular regulators in cancer.In vivo imaging of protease activity by Probody therapeutic activation.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment.1(st) French-Israeli International Conference on B Cells and therapeutic antibodies: October 23-25, 2011 Jerusalem, Israel.Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer.Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.Third time lucky? Getting a grip on matrix metalloproteinases.Development of a periplasmic FRET screening method for protease inhibitory antibodies.Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors.Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.Generation of Highly Selective MMP Antibody Inhibitors.Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.Identification of matrix metalloproteinase-2 and -9 activities within the intestinal mucosa of dogs with chronic enteropathies.Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.8th international conference on management and rehabilitation of chronic respiratory failure: the long summaries – part 1.Selectivity Conversion of Protease Inhibitory Antibodies

P2860

Q27008735-3DA3C13F-6797-482A-AF60-C24E558FDA2F Q27015979-21D1E96F-0097-4EB1-AD22-2C61F8CC46EA Q27306938-827B7FFD-C6CC-489D-9E63-C3F47145A704 Q28288148-3047304B-6C41-459E-8094-27706D80E634 Q28386047-9C2305E5-F052-45BA-8C33-D34F202AAD01 Q28601582-F7C6CBB6-BF66-4DF7-9137-290CE2B652BC Q33757096-6BBA407D-E1A6-4B59-9C72-99B604663041 Q33766675-27130D25-952F-4A6A-B65D-C6F5CABF2687 Q34490917-5310A09D-AB97-4182-ADC8-8BD8007B242C Q35532904-4712F352-F281-403E-B77D-6A3542C65062 Q35544060-A75302AE-3E79-450B-98D6-5567CC02777D Q35892721-76DA2D69-9153-460B-9350-CEBEC551E95A Q35892939-5EA60CB2-D680-4EC2-B0D2-277D0294123E Q35893758-267D40FC-B748-4524-AC6E-A3CB6A25B0E3 Q36077428-ADE4A5D2-E358-404E-848F-DCDCB5E91E8B Q36222825-12313835-0ABE-466A-8AFE-4ADE904E8FAB Q36250325-4559B555-BDA8-424C-A30C-3FA41385E5BE Q36791870-74525AA8-BA0D-466E-86C9-112B27A23991 Q37581720-C99EA263-8E71-486F-AF43-E9F7C45E7C77 Q38168582-52404E5C-CC9E-4533-8D38-C2CC7D78793C Q38261141-DFC19689-B28E-43F2-A036-1FE28826ED3C Q38785433-43FF5195-8CCE-4374-ACE4-2BBC5643B0AB Q38821294-B8CC09FD-3C46-4824-A3D8-9501FDB4A155 Q38881849-48D8E2D5-A1D4-4347-8CB3-91DD617DACA9 Q42239363-CE631B8E-CCBA-40A9-9958-E1BAAFA934C5 Q42333451-2982489A-379E-43FF-88D6-9C400A131BB8 Q42720277-C04F1EB3-6D41-483A-BA14-E191B928BAA1 Q44304473-9392D6C3-3C66-4990-B8AE-0660CBE604EE Q46008674-3F12A82A-1CB6-4A65-B450-DCB29FCBB066 Q46033483-A3614863-0EF7-45F3-9695-B7E1C8440449 Q47117984-DF5F7541-5446-4242-BE40-DDFADEEBC342 Q47394596-A69EF935-804E-4609-9740-4D9DFA72B6A1 Q50109654-BE27E31F-0A8B-4AFD-9493-B035AD4AEBF2 Q50986872-4747EBBC-C276-4AF2-9EF7-AA7E498BEA3A Q51044896-44C468EF-C8CB-46AE-A549-C5A9A1DF6ADF Q52660146-DDEA4A47-D38C-4C8A-9D67-B479C7039A55 Q52688539-B3F5686F-2210-44E5-8277-6BC1FAEE5D1B Q55054583-0CD76A87-BA2C-4ED7-818B-D2921ADF14F5 Q58556656-2D0C24CE-5065-4792-BE00-F47AF96AEF91

P2860

Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential

http://www.wikidata.org/entity/Q27676429

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Antibodies targeting the catal ...... ses show therapeutic potential

@ast

Antibodies targeting the catal ...... ses show therapeutic potential

@en

Antibodies targeting the catal ...... ses show therapeutic potential

@nl

type

label

Antibodies targeting the catal ...... ses show therapeutic potential

@ast

Antibodies targeting the catal ...... ses show therapeutic potential

@en

Antibodies targeting the catal ...... ses show therapeutic potential

@nl

prefLabel

Antibodies targeting the catal ...... ses show therapeutic potential

@ast

Antibodies targeting the catal ...... ses show therapeutic potential

@en

Antibodies targeting the catal ...... ses show therapeutic potential

@nl

P1433

Q27676429-14DDCBEC-5271-496F-8FD9-9FB81D226CE6

P1476

Q27676429-9C0442E0-B6DB-4179-A66A-61BDA10F54F2

P2093

Q27676429-23B20A25-FF4A-4627-8D69-7DCE813ABB61

Q27676429-27E24974-604C-49B7-8A44-85E1FD0CDB78

Q27676429-2DD7B540-E2AF-40AB-84A3-D4A070E99A5E

Q27676429-386ED6CB-C9AD-440C-B61E-1D11D39E7D13

Q27676429-5DB22C85-F05E-401F-B05E-6DDECCC46DE7

Q27676429-7ADEEFAD-7A27-4A65-B159-F3C3D314C15D

Q27676429-7BABA88E-787F-447F-87A4-AFA1F4C04A64

Q27676429-840B3AD6-A800-45F9-88CF-343168A518DC

Q27676429-8EF7E2A2-09F4-4B62-A32D-75D83D166B62

Q27676429-DC9F114B-1901-46C7-8B67-F8F6A6B51F75

P2860

Q27676429-047DE8B8-A529-467D-8654-FC73DA4ECD61

Q27676429-05ED2468-9568-41FC-A3C9-7F38FD0040F8

Q27676429-06475AA1-D0B2-4259-95EE-C2C7FBEEDAD5

Q27676429-1C5A4FE5-1033-4CEC-9D9F-CA23F2A07370

Q27676429-1C9A9777-A883-41B8-A148-C06100F6D462

Q27676429-24446C2E-79A1-4A62-8589-4E6325794A37

Q27676429-2CB1A1A9-B557-4CA7-922F-42D42511AFDA

Q27676429-359B5EC1-E806-4240-9538-E4A64BE15955

Q27676429-3BFEF030-1642-410D-A310-FD411441AA53

Q27676429-40C28CAE-7735-4A65-A4D9-B86CFEE6FCDE

P2888

Q27676429-2BB9DEB1-204F-4DDC-BE83-782C618AB5A3

P304

Q27676429-01F64319-492E-4D30-AF14-A27428B61D52

P31

Q27676429-DA3EA739-026B-4EAC-8D57-2B43C840C925

P356

Q27676429-EBF25EC1-4400-49D1-A7E3-EF8AE1FB2CC8

P407

Q27676429-C39D4CB7-9C68-4AB8-8C97-FD51D916985D

P433

Q27676429-CF3715CE-56A8-4BB4-BD5E-5E0C068D249D

P478

Q27676429-586AFAC3-4A72-4828-88C2-E2A58B1886B8

P50

Q27676429-7BAE9755-C6A7-415F-81FB-00838C2AEC8C

Q27676429-8389253E-50A8-45DA-B632-CA7E4BD1A14F

P577

Q27676429-0D79C7E6-4D1D-4920-BEC2-3450C3C80679

P5875

Q27676429-8873B60B-B352-4861-BAF9-E1128927E8C7

P6179

Q27676429-4B4F0DAF-B48B-4249-B677-C6356C39C864

P698

Q27676429-83022EFB-56F6-4D02-8D6B-92E1F0136691

P921

Q27676429-21923C72-9860-4702-92B8-BE0B527407DB

P356

P1433

Nature Medicine

P1476

Antibodies targeting the catal ...... ses show therapeutic potential

@en

P2093

Abraham Shanzer

http://www.w3.org/2001/XMLSchema#string

Irit Sagi

http://www.w3.org/2001/XMLSchema#string

Netta Sela-Passwell

http://www.w3.org/2001/XMLSchema#string

Ori Brenner

http://www.w3.org/2001/XMLSchema#string

Orly Dym

http://www.w3.org/2001/XMLSchema#string

Raanan Margalit

http://www.w3.org/2001/XMLSchema#string

Raghavendra Kikkeri

http://www.w3.org/2001/XMLSchema#string

Rina Arad-Yellin

http://www.w3.org/2001/XMLSchema#string

Tamar Danon

http://www.w3.org/2001/XMLSchema#string

Tsipi Shoham

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed

Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor

The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function

Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

Inflammatory bowel disease

Matrix metalloproteinases and the regulation of tissue remodelling

Structure and function of matrix metalloproteinases and TIMPs

Quantitative analysis of intravenously administered contrast media reveals changes in vascular barrier functions in a murine colitis model.

Conformational variability of matrix metalloproteinases: beyond a single 3D structure.

P2888

P304

143-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2582

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Miriam Eisenstein

P577

2011-12-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51924001

http://www.w3.org/2001/XMLSchema#string

P6179

1052241679

http://www.w3.org/2001/XMLSchema#string

P698

22198278

http://www.w3.org/2001/XMLSchema#string

P921